内分泌学的検査のパイプライン - 開発段階、セグメント、地域、規制経路、主要企業

当レポートでは、内分泌学的検査のパイプライン製品について調査分析し、各開発段階における製品の比較分析や、進行中の臨床試験のデータを含む、包括的な情報を提供しています。

目次

第1章 目次

第2章 イントロダクション

第3章 開発中の製品

• 内分泌学的検査 - パイプライン製品：開発段階別
• 内分泌学的検査 - パイプライン製品：セグメント別
• 内分泌学的検査 - パイプライン製品：地域別
• 内分泌学的検査 - パイプライン製品：規制経路別
• 内分泌学的検査 - パイプライン製品：推定承認日別

第4章 内分泌学的検査 - 開発中のパイプライン製品：企業別

• 内分泌学的検査企業 - パイプライン製品：開発段階別
• 内分泌学的検査 - パイプライン製品：開発段階別

第5章 内分泌学的検査の企業と製品の概要

第6章 内分泌学的検査 - 最近の発展

第7章 付録

Abstract

GlobalData's Medical Devices sector report, "Endocrinology Tests Pipeline Report including Stages of Development, Segments, Region and Countries, Regulatory Path and Key Companies, 2023 Update" provides comprehensive information about the Endocrinology Tests pipeline products with comparative analysis of the products at various stages of development and information about the clinical trials which are in progress.

Endocrinology Tests are the reagents used for quantification and detection of endocrine hormones secreted in the human body.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

• Extensive coverage of the Endocrinology Tests under development
• The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
• The report reviews the major players involved in the development of Endocrinology Tests and list all their pipeline projects
• The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
• The report provides key clinical trial data of ongoing trials specific to pipeline products
• Recent developments in the segment / industry

Reasons to Buy

The report enables you to -

• Formulate significant competitor information, analysis, and insights to improve R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter strategies to gain competitive advantage
• Identify and understand important and diverse types of Endocrinology Tests under development
• Develop market-entry and market expansion strategies
• Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
• In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

• 1.1 List of Tables
• 1.2 List of Figures

2 Introduction

• 2.1 Endocrinology Tests Overview

3 Products under Development

• 3.1 Endocrinology Tests - Pipeline Products by Stage of Development
• 3.2 Endocrinology Tests - Pipeline Products by Segment
• 3.3 Endocrinology Tests - Pipeline Products by Territory
• 3.4 Endocrinology Tests - Pipeline Products by Regulatory Path
• 3.5 Endocrinology Tests - Pipeline Products by Estimated Approval Date

4 Endocrinology Tests - Pipeline Products under Development by Companies

• 4.1 Endocrinology Tests Companies - Pipeline Products by Stage of Development
• 4.2 Endocrinology Tests - Pipeline Products by Stage of Development

5 Endocrinology Tests Companies and Product Overview

6 Endocrinology Tests- Recent Developments

• 6.1 Aug 31, 2023: Integrated Diagnostics Holdings Announces Half Year Report
• 6.2 Jun 12, 2023: Abbott Names Philip Boudreau CFO effective Sept. 1
• 6.3 Jun 07, 2023: Eckert & Ziegler Strahlen Annual General Meeting Approves Dividend of EUR 0.50 per Share
• 6.4 Jun 01, 2023: Integrated Diagnostics announces Q1 2023 Results
• 6.5 Apr 06, 2023: Integrated Diagnostics Holdings Announces Final Results
• 6.6 Apr 06, 2023: Integrated Diagnostics Holdings concludes 2022 reporting solid 18% growth in non-Covid revenues
• 6.7 Feb 22, 2023: Novo Nordisk Notice for the Annual General Meeting
• 6.8 Dec 20, 2022: Eckert & Ziegler Announces Changes in the Supervisory Board
• 6.9 Dec 19, 2022: Eckert & Ziegler Announces Changes in the Management Board
• 6.10 Nov 17, 2022: Integrated Diagnostics Holdings 3rd Quarter Results
• 6.11 Oct 31, 2022: IDH and its Jordanian subsidiary, Biolab, to Launch Greenfield Diagnostic Venture in Saudi Arabia in Partnership with Izhoor Medical, a company owned by Fawaz Alhokair
• 6.12 Oct 05, 2022: DiaSorin Gets $31M BARDA Funding for Point-of-Care Instrument

7 Appendix

• 7.1 Methodology
• 7.2 About GlobalData
• 7.3 Contact Us
• 7.4 Disclaimer